Scientific rationale for the use of remdesivir in patients with COVID-19


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

Results from several randomized clinical trials of remdesivir show that patients who received remdesivir, had clinical improvement compared with patients who received placebo, as well as reduced disease progression in patients requiring oxygen therapy. Clinical trials have not obtained convincing data on the effect of the drug on outcomes incl. death from COVID-19. In accordance with the instructions for use of the drug remdesivir against SARS-CoV-2: use only in inpatient settings and only for patients with saturation less than 94% or who need some form of respiratory support.

Full Text

Restricted Access

About the authors

V. M Tsvetov

Federal Center for Cardiovascular Surgery

K. B Mirzaev

Russian Medical Academy of Continuous Professional Education

References

  1. Agostini M.L., Andres E.L., Sims A.C., et al. Coronavirus Susceptibility to the Antiviral Remdesivir (GS-5734) Is Mediated by the Viral Polymerase and the Proofreading Exoribonuclease. mBio. 2018;9(2):e00221-18. Doi: 10.1128/ mBio.00221-18.
  2. Sheahan T.P, Sims A.C., Graham R.L., et al. Broad-spectrum antiviral GS-5734 inhibits both epidemic and zoonotic coronaviruses. Science Translational Medicine. 2017;9(396):eaal3653. Doi: 10.1126/ scitranslmed.aal3653.
  3. Sheahan T.P., Sims A.C., leistS.R., et al. Comparative therapeutic efficacy of remdesivir and combination lopinavir, ritonavir, and interferon beta against MERS-CoV. Nat Commun. 2020;11:222 https:// doi.org/10.1038/s41467-019-13940-6
  4. Singapore approves remdesivir drug for emergency COVID-19 treatment. Reuters. Retrieved 10 June 2020.
  5. Wang M., Cao R., Zhang L. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Research. 2020;30(3):269-71. Doi: 10.1038/ s41422-020-0282-0.
  6. FDA Allows For ‘Emergency Use' of Remdesivir, Experimental Coronavirus Drug. TIME. ASSOCIATED PRESS (1 May 2020).
  7. Flerman Steve. Coronavirus Treatment Breakthrough Announced, Voice of America (29 April 2020). URL: https://www.voanews.com/covid-19-pandemic/coronavirus-treatment-breakthrough-announced
  8. NIF Clinical Trial Shows Remdesivir Accelerates Recovery from Advanced COVID-19. National Institute of Allergy and Infectious Diseases (NIAID) (29 April 2020) URL: https://www.niaid.nih.gov/ news-events/nih-clinical-trial-shows-remdesivir-accelerates-recovery-advanced-covid-19
  9. Ученые подтвердили эффективность ремдесивира в лечении коронавируса. Би-би-си BBC News Русская служба. [Scientists have confirmed the effectiveness of remdesivir in the treatment of coronavirus. BBC BBC News Russian Service. (In Russ.)]. URL: https://www.bbc.com/russian/ news-52490929
  10. Beigel J.H., Tomashek K.M., Dodd L.E., et al. Remdesivir for the Treatment of Covid-19 -Preliminary Report. N Engl J Med. 2020. Published online ahead of print, 2020 May 22. Doi:10.1056/ NEJMoa2007764.
  11. Gotzsche P C. Remdesivir against coronavirus, hope or hype? Copenhagen: Institute for Scientific Freedom, 2020. 1 June. URL: https:// www.sciestificfrecdom.dk/wp-content/ uploads/2020/06/G0tzsche-Remdesivir-againstcoronavirus-hope-or-hype.pdf
  12. Goldman J.D., Lye D.C.B., Hui D.S., et al. Remdesivir for 5 or 10 Days in Patients with Severe Covid 19. N Engl J Med. 2020;383(19):1827-37. doi: 10.1056/NEJMoa2015301
  13. Search of: remdesivir - List Results - ClinicalTrials.gov. URL: https://clinicaltrials.gov/ct2/results?cond=&term=&type=&rslt=&age_v=&gndr=&intr=Remdesivir (date of access:20.10.2020).
  14. World Health Organization (WHO) (2020) Clinical management of COVID-19. Interim Guidance. 27 May. Accessed 9 June 2020. URL: https:// www.who.int/pubrications/i/item/crinical-management-of-covid-19
  15. Frequently Asked Questions on the Emergency Use Authorization for Remdesivir for Certain Hospitalized COVID-19 Patients. URL: https:// www.fda.gov/meWia/137574/download
  16. COVID-19 Update: Elusive Complication, Remdesivir Toxicity, Medscape Medical News, Caroline Cassels. July 08, 2020. URL: https:// www.meWscapo.com/viewarficle/933623?src=ip hone&ref=email#vp_1
  17. Государственный реестр лекарственных средств, реестр разрешений на проведение клинических исследований (РКИ). [State register of medicines, register of approvals for clinical trials (RCT). (In Russ.)]. URL: https://grls.rosminzdrav.ru/CiPermitionReg. aspx?Torg=ремдесивир (дата обращения/date of access: 20.10.2020).
  18. Государственный реестр лекарственных средств. [State register of medicines. (In Russ.)].URL: h ttp://grls. rosm inzWrav. ru/G RLS.aspx ?Reg Number =&MnnR=Ремдесивир&lf=&TradeNmR=&Owne rName=&MnfOrg=&MnfOrgCoun try=&isfs=0&is ND=-1®type=1&pageSize=10&order=RegDat e&orderTypo=Wesc&pageNum=1
  19. RomWosivir for the Treatment of Covid-19 - Final Report. N Engl J MoW. 2020 Oct 8;NEJMoa2007764. Doi: 10.1056/ NEJMoa2007764.
  20. Wang Y, Zhou F, Zhang D., et al. Evaluation of the efficacy and safety of intravenous remdesivir in adult patients with severe COVID-19: study protocol for a phase 3 randomized, doubleblind, placebo-controlled, multicentre trial. Trials. 2020;21(1):422. doi: 10.1186/s13063-020-04352-9.
  21. Effect of RomWosivir vs Standard Care on Clinical Status at 11 Days in Patients With Moderate COVID-19: A Randomized Clinical Trial. JAMA. 2020;324(11):1048-1057. Doi: 10.1001/ jama.2020.16349.
  22. WHO Director-General’s opening remarks at the media briefing on COVID-19. 16 October 2020 URL: https://www.who.int/dg/speeches/detail/who-director-general-s-opening-remarks-at-the-media-briefing-on-covid-19---16-october-2020
  23. Repurposed antiviral drugs for COVID-19 -interim WHO SOLIDARITY trial results. Doi:https://doi.org/10.1101/2020.10.15.20209817
  24. FDA Approves Veklury. URL: https://www.dmgs. com/newdrugs/fda-approves-veklury-remdesivir-covid-19-5368.html
  25. Временные методические рекомендации. Профилактика, диагностика и лечение новой коронавирусной инфекции (COVID-19). 9-е изд. М., 2020. 235 c.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2020 Bionika Media

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies